Michael S. Weiss
CIK: 0001038977
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Mar 18, 2026FBIO
Fortress Biotech, Inc.
Award(A)Direct475.4K shares- - Jan 8, 2026TGTX
TG THERAPEUTICS, INC.
Award(A)Direct622K shares- - Nov 5, 2025TGTX
TG THERAPEUTICS, INC.
Gift(G)Direct3.9M shares- - Nov 5, 2025TGTX
TG THERAPEUTICS, INC.
Gift(G)Direct803.7K shares- - May 30, 2025CKPT
Checkpoint Therapeutics, Inc.
Tender Offer(U)Indirect187K shares- - May 29, 2025CKPT
Checkpoint Therapeutics, Inc.
Award(A)Direct50K shares at avg. $1.29$65K - May 28, 2025CKPT
Checkpoint Therapeutics, Inc.
Award(A)Indirect12.2K shares- - Jan 29, 2025TGTX
TG THERAPEUTICS, INC.
Award(A)Direct750K shares- - Jan 1, 2025FBIO
Fortress Biotech, Inc.
Award(A)Direct454.2K shares- - Dec 13, 2024CKPT
Checkpoint Therapeutics, Inc.
Award(A)Indirect12.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 18, 2026 |  FBIO Fortress Biotech, Inc. | Award(A) | 475,424 | - | $0 | Direct |
| Jan 8, 2026 |  TGTX TG THERAPEUTICS, INC. | Award(A) | 622,000 | - | $0 | Direct |
| Nov 5, 2025 | TGTX TG THERAPEUTICS, INC. | Gift(G) | 3,865,126 | - | - | Direct |
| Nov 5, 2025 | TGTX TG THERAPEUTICS, INC. | Gift(G) | 803,717 | - | - | Direct |
| May 30, 2025 |  CKPT Checkpoint Therapeutics, Inc. | Tender Offer(U) | 187,007 | - | - | Indirect |
| May 29, 2025 | CKPT Checkpoint Therapeutics, Inc. | Award(A) | 50,000 | $1.29 | $64,500 | Direct |
| May 28, 2025 | CKPT Checkpoint Therapeutics, Inc. | Award(A) | 12,195 | - | - | Indirect |
| Jan 29, 2025 | TGTX TG THERAPEUTICS, INC. | Award(A) | 750,000 | - | $0 | Direct |
| Jan 1, 2025 | FBIO Fortress Biotech, Inc. | Award(A) | 454,153 | - | $0 | Direct |
| Dec 13, 2024 | CKPT Checkpoint Therapeutics, Inc. | Award(A) | 12,638 | - | $0 | Indirect |
1-10 of 10 transactions
About WEISS MICHAEL S
WEISS MICHAEL S (SEC CIK 0001038977) files insider reports with the SEC as Executive Vice Chairman of Fortress Biotech, Inc. (FBIO), CEO of TG THERAPEUTICS, INC. (TGTX) and Director of Checkpoint Therapeutics, Inc. (CKPT).
Signal8 holds 7 ownership filings by WEISS MICHAEL S, all Form 4s, filed between Dec 17, 2024 and Mar 20, 2026. Those filings report 10 transactions, from Dec 13, 2024 to Mar 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on WEISS MICHAEL S's filings is in BAY HARBOR ISLANDS, FL.
Recent filings by WEISS MICHAEL S
- Mar 18, 2026: Grant or award of FBIO shares (Form 4, code A).
- Jan 8, 2026: Grant or award of TGTX shares (Form 4, code A).
- Nov 5, 2025: Gifts of TGTX shares (2 lines, Form 4, code G).
- May 30, 2025: Tender of shares transaction of CKPT shares (Form 4, code U).
- May 29, 2025: Grant or award of CKPT shares (Form 4, code A).
Other insiders filing for Fortress Biotech, Inc. (FBIO)
- Jin David, Chief Financial Officer
- ROSENWALD LINDSAY A MD, PRESIDENT, CEO & CHAIRMAN
- Klein Dov, Director
- Harvey Jimmie, Director
- Lorenz Kevin, Director
- Hoenlein Malcolm, Director